medigraphic.com
ISSN 0016-3813 (Impreso)

2008, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2008; 144 (3)


Terapia antiangiogénica ocular: experiencia clínica en México

Quiroz-Mercado H, Vélez-Montoya R, Fromow-Guerra J, Guerrero-Naranjo JL, Moreno-Páramo D, Morales-Cantón V

Idioma: Español
Referencias bibliográficas: 59
Paginas: 245-253
Archivo PDF: 136.54 Kb.


RESUMEN

La angiogénesis patológica retiniana es la causa principal de pérdida visual en una gran cantidad de enfermedades: degeneración macular relacionada a la edad, retinopatía diabética y retinopatía del prematuro, en otras. Estas últimas dos son, además, problemas de salud pública en los países en desarrollo. Estudios recientes sobre la fisiopatología de estas enfermedades han demostrado el papel fundamental que los factores de crecimiento tienen sobre la angiogénesis. La terapia antiangiogénica ocular nació como un esfuerzo de inhibir la acción de estos factores sobre la angiogénesis patológica y preservar la visión. El objetivo de esta revisión es hacer un recuento de la experiencia en México en cuanto a esta modalidad terapéutica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hutcheson KA. Retinopathy of prematurity. Curr Opin Ophthalmol 2003;14:286-290.

  2. Gariano RY, Kalina RE, Hendrickson AE. Normal and pathological mechanisms in retinal vascular development. Surv Ophthalmol 1996;40:481-490.

  3. Flynn JT, Chan-LingT. Retinopathy of prematurity: Two distinct mechanism hat underline zone 1 and zone 2 disease. Am J Ophthalmol 2006;142:46-59.

  4. Kvanta A. Ocular Angiogenesis: The role of growth factors. Acta Ophthalmol Scand 2006;84:282-288.

  5. Yoo MH, Hyun HJ, Kob JY, Yoon YH. Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyoeroxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci 2005;46:4780-4787.

  6. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv Ophthalmol 2007;52:S3-S19.

  7. Lashkari K. Hirose T, Yazdany J, McMeel JW, Kazlauskas A. Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advance retinopathy of prematurity. Am J Pathol 2000;156:1337-1344.

  8. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-1228.

  9. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, et al. Low IGFI suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001;98:5804-5808.

  10. Madanlou HD, Gharraee Z, Hasan J, Waltzman J, Nageotte S, Beharry KD. Ontogeny of VEGF, IGF-I and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest Ophthalmol Vis Sci 2006;47:738-744.

  11. Schlingemann RO, van Hinsbergh VW. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br J Ophthalmol 1997;81:501-512.

  12. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 2006;12:5018-5022.

  13. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 1998;21:143-156.

  14. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002;16:242-260.

  15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005:36:331-335.

  16. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:607-606.

  17. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.

  18. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.

  19. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion. Retina 2006;26:279-284.

  20. Quiroz-Mercado H, García CA, Uwaydat S, Sepúlveda-Flores RN, Meza-de Regil A, Holroyd K, et al. A Phase I/II trial of intravenous squalamine lactate infusion for treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (ARMD). 5th International Symposium on Ocular Pharmacology and Therapeutics ISOPT, Monte Carlo (Monaco), March 11-14, 2004.

  21. Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, López- Barrera F, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci 2005;46:2947-2953.

  22. Lee H, Struman I, Clapp C, Martial J, Weiner RI. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: Activation of plasminogen activator inhibitor 1 expression. Endocrinology 1998;139:3696-3703.

  23. Dueñas Z, Rivera JC, Quiroz-Mercado H, Aranda J, Macotela Y, Montes de Oca P, et al. Prolactin in eyes of patients with retinopathy of prematurity: Implications for vascular regression. Invest Ophthalmol Vis Sci 2004;45:2049-2055.

  24. Clapp C, Aranda J, González C, Jeziorski MC, Martínez-de la Escalera G. Vasoinhibins: Endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 2006;17:301-307.

  25. Rivera J, Moreno-Páramo D, Aranda J, et al. Prolactin decreases in the circulation of patients with proliferative diabetic retinopathy: Relationship to intraocular vasoinhibins. ARVO 2007, resumen 1408/B464.

  26. Stone J, Itim A, Alon T, Pe’er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.

  27. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005;353: 839-841.

  28. Murakami T, Suzuma K, Takagi H, Kita M, Ohashi H, Watanabe D, et al. Time-lapse imaging of vitreoretinal angiogenesis originating from both quiescent and mature vessels in a novel ex vivo system. Invest Ophthalmol Vis Sci 2006;47:5529-5536.

  29. Madan A. Angiogenesis and antiangiogenesis in the neonate. Relevance to retinopathy of prematurity. NeoReviews 2003;4:456-464.

  30. Hague S, MacKenzie IZ, Bicknell R, Rees MC. In-vivo angiogenesis and progestogens. Hum Reprod 2002;17:786-793.

  31. US Food and Drug Administration. FDA approves first angiogenesis inhibitor to treat colorectal cancer. February 26, 2004. Disponible en http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html

  32. Quiroz-Mercado H, Ustariz-González O, Martínez-Castellanos MA, Covarrubias P, Domínguez F, Sánchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: The importance of being part of a developing story. Semin Ophthalmol 2007;22:109-125.

  33. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D’Amico DJ, Flynn HW, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19.

  34. Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;353:747-748.

  35. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.

  36. Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest 1995;72:615-618.

  37. Abraham-Marín ML, Cortés-Luna CF, Álvarez-Rivera G, Hernández-Rojas M, Quiroz-Mercado H, Morales-Cantón V. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007;245:651-655.

  38. Ustariz-González O, Abraham-Marín ML, Gordon-Angelozzi M, Suárez- Licona A, Kon-Jara V, Torres-Soriano M, et al. Treatment of choroidal neovascularization (CNV) associated with age related macular degeneration (AMD) with photodynamic therapy and bevacizumab (Avastin) injection. ARVO 2007, resumen 290/B343.

  39. Martínez-Castellanos MA, Parrochia M, Quiroz-Mercado H, Guerrero- Naranjo JL, Ustariz O, Abraham ML, et al. Safety and efficacy of intravitreal bevacizumab for idiopathic subfoveal choroidal neovascularization. Pilot Study. ARVO 2006, resumen 4282/B343.

  40. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow- Guerra J, Amaya-Espinosa A, Solís-Vivanco A, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.

  41. Concha L, Kon V, Unzueta J, Navarro P, Arellanes L. Intravitreal bevacizumab for the treatment of neovascular membrane in patients with intraocular inflammation. ARVO 2007, resumen 5144/B292.

  42. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arévalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.

  43. Arévalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sánchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Result from the Pan-American Collaborative Retina Study Group at 6-month follow–up. Ophthalmology 2007;114:743-750.

  44. García-Aguirre G, Reyna-Castelán E, Torres-Soriano ME, Kon-Jara V, Quiroz-Mercado H. Intravitreal bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: A contralateral eye study. ARVO 2007, resumen 3349/B496.

  45. Guerrero-Naranjo JL, Morales-Cantón V, Fromow-Guerra J, Álvarez-Rivera G, Solís-Vivanco A, Reyna-Castelán E, et al. Intravitreal bevacizumab (Avastin) as treatment for macular edema in vein occlusions. Cannes Retina Festival 2006, ASRS and EVRS Meeting, resumen 345.

  46. Ustariz-González O, Suárez-Licona A, Quiroz-Mercado H, Guerrero-Naranjo JL, Pérez-Reguera A, Moreno-Páramo D, et al. Bevacizumab injection in Von Hippel Lindau disease. ARVO 2006, resumen 4713/B1048.

  47. Romo-García E, Álvarez-Rivera G, Gordon M, Kon-Jara V, Martínez- Castellanos MA, Moreno-Páramo D, et al. Is bevacizumab an effective treatment for coats disease? ARVO 2007, resumen 4552/B233.

  48. Salazar-Terán N, Kon-Jara K, Ustariz-González O, Reyna-Castelán E, Fromow-Guerra F, Quiroz-Mercado H. Does avastin change evolution in juxtafoveal telangiectasias? ARVO 2007, resumen 4552/B233.

  49. D’Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994;35:3974-3979.

  50. Villegas-Becerril E, González-Fernández R, Fernández-Molina F, Gallardo-Galera JM. Growth factor levels and ROP. Ophthalmology 2005;112:2238.

  51. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.

  52. Stone J, Chan-Ling T, Pe’er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996;37:290-299.

  53. Bhisitkul RB. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-1547.

  54. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a Targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132.

  55. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:642-644.

  56. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGFinduced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241-248.

  57. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47:86-92.

  58. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13:225-234.

  59. Campochiaro PA, C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-931.




2020     |     www.medigraphic.com